
Novavax Inc
NVAXHealthcare|Biotechnology|USA
$9.33
-0.07 (-0.74%)
Earnings Power
$97.87
About
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Stock Price
+31.4%(1Y)
Pipeline Summary
53 total trials15
Phase 1
28
Phase 2
18
Phase 3
3
Phase 4
Completed: 48Withdrawn: 3Terminated: 1Active: 1
Active Trials (1)
Efficacy and Safety of NVX-CoV2705
NCT07086222COVID-19
Phase 4Active
Enrollment: 6,500 participants
BioScore
6.7/10
Buy
Ownership
Recent Insider Trades
YOUNG JAMES FSELL
2024-12-3110,000 shares @ $8.22
King Rachel K.SELL
2024-12-134,150 shares @ $9.02
YOUNG JAMES FSELL
2024-06-217,500 shares @ $14.09
YOUNG JAMES FSELL
2024-06-187,500 shares @ $13.72
Dubovsky FilipSELL
2024-06-1713,904 shares @ $14.47
Recent News
2026-06-24 13:04:39
2026-06-18 18:00:30
Data last updated: Jul 12, 2026, 07:38 PM